LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Celldex Therapeutics Inc

Open

SectorHealthcare

24.14 4.28

Overview

Share price change

24h

Current

Min

22.95

Max

24.14

Key metrics

By Trading Economics

Income

-2.8M

-57M

Sales

35K

730K

Profit margin

-7,753.425

Employees

186

EBITDA

-1.1M

-63M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+129.03% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

19M

1.5B

Previous open

19.86

Previous close

24.14

News Sentiment

By Acuity

100%

0%

360 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Sept 2025, 23:59 UTC

Acquisitions, Mergers, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 Sept 2025, 22:02 UTC

Major Market Movers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 Sept 2025, 17:01 UTC

Major Market Movers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 Sept 2025, 17:01 UTC

Major Market Movers

Tron Shares Rise After New Investment From Bravemorning

8 Sept 2025, 16:14 UTC

Major Market Movers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 Sept 2025, 16:13 UTC

Major Market Movers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 Sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 Sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 Sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 Sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 Sept 2025, 21:47 UTC

Major Market Movers

Microsoft Signs $17.4B AI Deal With Nebius

8 Sept 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 Sept 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 Sept 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 Sept 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 Sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 Sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 Sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 Sept 2025, 16:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 Sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 Sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 16:16 UTC

Earnings

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

129.03% upside

12 Months Forecast

Average 52.38 USD  129.03%

High 67 USD

Low 38 USD

Based on 10 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat